Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

Logo
JNJ US​

Johnson & Johnson(JNJ US)

$263.81-3.801.42%Ext:$265.87+2.060.78%(Market Closed · 23:59:31 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings
EDINET Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Johnson & Johnson — Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UN
CEO
Joaquin Duato
Headquarters
New Brunswick, NJ, US
Employees
141,700
Website
www.jnj.com

Key Metrics

Price
$256.03
Market Cap
$617.01B
Revenue (TTM)
$25.31B
Net Income (TTM)
$5.53B
EPS (TTM)
2.27
P/E (TTM)
29.33
P/B (TTM)
7.60
Dividend Yield
2.28%
ROE (TTM)
6.45%
ROA (TTM)
2.61%
Operating Margin
26.58%
Beta
-0.11

Dividends

Last Dividend
$1.34
Last Yield
0.02%

Summary

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Website
www.jnj.com
Location
New Brunswick, NJ, US
Phone732 524 0400
Employees141,700
CEOJoaquin Duato
Sector
Health Care
Industry
Pharmaceuticals

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(3.3K)

Expand
  • 10-QQ3ended 27 Sept 202621 Oct
  • 8-KResults of Operations and Financial Condition13 Oct
  • 4Statement of changes in beneficial ownership10 Sep
  • 4Statement of changes in beneficial ownership10 Sep
  • 4Statement of changes in beneficial ownership10 Sep
  • 4Statement of changes in beneficial ownership4 Sep
  • 144Schmid Timothy2 Sep
  • 3Initial statement of beneficial ownership1 Sep
  • 4Statement of changes in beneficial ownership18 Aug
  • 144Taubert Jennifer L17 Aug
  • 4Statement of changes in beneficial ownership14 Aug
  • 144Duato Joaquin13 Aug
  • N-PXAnnual report of proxy voting record10 Aug
  • 4Statement of changes in beneficial ownership7 Aug
  • 4Statement of changes in beneficial ownership7 Aug
  • 144Forminard Elizabeth6 Aug
  • 13F-HRQuarterly report (institutional investment manager holdings)6 Aug
  • 144Duato Joaquin5 Aug
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers4 Aug
  • 8-KRegulation FD Disclosure29 Jul

EDINET Filings(21)

Expand
  • 10-KAnnual Securities Report (2024.12.30-2025.12.28)25 Jun
  • IRCorrection Extraordinary Report3 Mar
  • PRSAmended Securities Registration Statement3 Mar
  • IRExtraordinary Report27 Feb
  • PRSSecurities registration statement27 Feb
  • IRSemi-Annual Report (2024.12.30-2025.06.29)25 Sep 2025
  • 10-KAnnual Securities Report (2024.01.01-2024.12.29)26 Jun 2025
  • PRSSecurities registration statement26 Feb 2025
  • IRExtraordinary Report26 Feb 2025
  • IRSemi-Annual Report (2024.01.01-2024.06.30)27 Sep 2024
  • PRSSecurities registration statement30 Aug 2024
  • 10-KAnnual Securities Report (2023.01.02-2023.12.31)28 Jun 2024
  • IRExtraordinary Report16 May 2024
  • PRSSecurities registration statement11 May 2022
  • 10-KAnnual Securities Report (2019.12.30-2021.01.03)24 Jun 2021
  • PRSSecurities registration statement6 May 2021
  • 10-KAnnual Securities Report (2018.12.31-2019.12.29)24 Jun 2020
  • 10-KAnnual Securities Report (2018.01.01-2018.12.30)27 Jun 2019
  • 10-KAmended Annual Securities Report26 Mar 2018
  • 10-KAnnual Securities Report (2016.01.04-2017.01.01)30 Jun 2017

News

  • Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer09:00AM
  • Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer08:54AM
  • NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma07:00AM
  • AMG Asset Management Group Inc. Purchases 2,436 Shares of Johnson & Johnson $JNJ05:32AM
  • Johnson & Johnson $JNJ Stock Holdings Cut by Cooke & Bieler LP05:32AM
  • Johnson & Johnson $JNJ Stock Sold by Crossmark Global Holdings Inc.04:56AM
  • 39,667 Johnson & Johnson $JNJ Shares Sold by Axxcess Wealth Management LLC04:56AM
  • Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial04:18AM
  • J&J Stock Reclaims 50-Day SMA: Is it Time to Buy, Sell or Hold?23 Oct
  • UK approves J&J's oral psoriasis pill23 Oct
  • 2,609 Johnson & Johnson $JNJ Shares Sold by Diversify Advisory Services LLC23 Oct
  • Johnson & Johnson $JNJ Stock: Cohen Investment Advisors LLC Reduces Position23 Oct
  • Procter & Gamble Jumps 6% as Earnings Beat Draws Defensive Buyers; Johnson & Johnson Rises 3%, Coca-Cola Ticks Up22 Oct
  • JNJ Stock Has a New Growth Story, but One Business Needs to Catch Up22 Oct
  • Social Security Isn't Enough: 5 Secure Dividend Stocks to Fund Your Retirement22 Oct
  • Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 202622 Oct
  • Johnson & Johnson Raised Its Dividend Every Year. Why Did It Trail the S&P 500?21 Oct
  • Treasury Yields Are Near 5%. Should Retirees Rethink Dividend Stocks?21 Oct
  • 3 of the Best Value Stocks to Own21 Oct
  • Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?21 Oct

Mentions in Filings

  • Corps, and Assistant Bureau Director for Health Services and Medical Director of the Federal Bureau of Prisons. From 2007, Dr. Moritsugu was the VP for Global Professional Education and Strategic Relations for <strong>Johnson & Johnson</strong>’s Diabetes Solutions Companies, and former Worldwide Chairman of the Johnson & Johnson (JJDI), until his retirement from Johnson & Johnson in 2013. He served as the Interim Chief Science and Medical Officer of the American …
    Blue Acquisition Corp/CaymanJohnson & Johnson·DEFM14A - Definitive proxy statement (merger)·Q4 26·23 Oct
  • … rvice Corps, and Assistant Bureau Director for Health Services and Medical Director of the Federal Bureau of Prisons. From 2007, Dr. Moritsugu was the VP for Global Professional Education and Strategic Relations for <strong>Johnson & Johnson</strong>’s Diabetes Solutions Companies, and former Worldwide Chairman of the Johnson & Johnson (JJDI), until his retirement from Johnson & Johnson in 2013. He served as the Interim Chief Science and Medical Officer of the Am …
    Blockfusion Digital Infrastructure, Inc.Johnson & Johnson·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·23 Oct
  • … a number of large pharmaceutical and biotechnology companies, such as Amgen Inc., Apogee Therapeutics, Inc. (acquired by AbbVie Inc.), AstraZeneca plc, Belenos Biosciences Inc., Generate Biomedicines, Inc., GSK plc, <strong>Johnson & Johnson</strong>, KeyMed Biosciences Inc., Eli Lilly and Company, Pfizer Inc., Sanofi S.A., and Upstream Bio, Inc. that currently market and sell drugs or are pursuing the development of drug candidates for the treatment of the indic …
    WINDWARD BIO GROUP AGJohnson & Johnson·F-1 - Registration statement (foreign issuer)·Q4 26·23 Oct
  • … red by Amgen, Inc. in April 2021) from December 2015 to June 2019 and as a member of the board of directors of Ambrx, Inc., a then-publicly held biopharmaceutical company, from February 2014 until its acquisition by <strong>Johnson & Johnson</strong> in June 2015. Dr. Gujrathi is a Co-Founder of Gossamer Bio, Inc., a publicly held biopharmaceutical company, and served as its President and Chief Executive Officer from July 2018 to November 2020 and as its Presiden …
    Bolt Biotherapeutics, Inc.Johnson & Johnson·8-K - Entry into a Material Definitive Agreement·Q4 26·23 Oct
  • … ile in 1L EGFR atypical NSCLC Note: ClinicalTrials.gov identifier: NCT05315700. Combination of enozertinib with SC amivantamab is being evaluated in a dedicated dose exploration trial via clinical collaboration with <strong>Johnson & Johnson</strong>. 16 --- Enozertinib Phase 1b Trial Enrolled 1L EGFR Atypical NSCLC Patients, Including an Exceptionally High Proportion with Baseline CNS Metastases Demographics and Baseline Characteristics Characteristic N=26 Cha …
    Oric Pharmaceuticals, Inc.Johnson & Johnson·EX-99.1 - 8-K - Regulation FD Disclosure·Q4 26·23 Oct
  • … cific antibody discovered and developed by Zymeworks and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by <strong>Johnson & Johnson</strong> using Zymeworks’ proprietary antibody engineering technologies. Zymeworks is advancing a diverse pipeline of novel biotherapeutics, leveraging its proprietary Azymetric™ platform and expertise in antibody-drug conju …
    Zymeworks Inc.Johnson & Johnson·EX-99.1 - 8-K - Entry into a Material Definitive Agreement·Q4 26·23 Oct

Key Stats

Trading

Px/Chg 1D$256.03 / -1.02%
Avg Volume8.11M
Beta-0.11
Mkt Cap617.01B
FD Mkt Cap641.50B

Float

Shrs Out/Float2.41B / 2.41B
Short Float0.01%
Days to Cover2.48
Stock Repurchased$4.03B

Current Valuation

EV650.31B
EV/EBITDA19.42
EV/Sales6.75
P/B7.60
P/S6.40
FCF Yield0.24%
ROE6.45%
ROA2.61%
Current Ratio1.03

Dividend

Cash$1.34
Yield2.28%
Yield (TTM)2.28%

Estimates

P/E29.33
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgApr '23Apr '24Apr '25Apr '26Oct '26
PRICE-BASED RATIOS
Price / Earnings75.46121.0310.4227.00107.36111.49
Price / Sales14.6617.974.304.2822.3624.38
Price / Book Value6.105.555.335.316.747.60
Price / Free Cash Flow117.1124.7920.0719.14100.38421.16
ENTERPRISE VALUE METRICS
Enterprise Value489,324.6452,769.3373,791.8392,280.6577,476.2650,305.3
Enterprise Value / Sales15.4219.104.394.4223.5125.69
Enterprise Value / EBITDA55.2973.6216.0315.8380.3190.65
Enterprise Value / EBIT70.33103.4223.6122.49111.4890.65

Financials

Full Financials
Millions USD5Yr CAGR (%)Jan '22Jan '23Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue4.6%78,740.079,990.085,159.088,821.094,193.0
Gross Income5.5%55,338.055,394.058,606.061,350.068,558.0
EBITDA11.3%26,751.026,605.023,320.024,781.041,055.0
EBIT14.7%19,361.019,635.015,834.017,442.033,552.0
Net Income6.4%20,878.017,941.035,153.014,066.026,804.0
EPS (Diluted)9%7.816.7313.725.7911.03
BALANCE SHEET
Cash & ST Inv-10.7%31,608.022,281.022,927.024,522.020,102.0
Total Assets2.3%182,018.0187,378.0167,558.0180,104.0199,210.0
Total Liabilities2.2%107,995.0110,574.098,784.0108,614.0117,666.0
Total Shareholder Equity2.4%74,023.076,804.068,774.071,490.081,544.0
CASH FLOW
Net Operating Cash Flow1.2%23,410.021,194.022,791.024,266.024,530.0
Cap Ex7.3%-3,652.0-4,009.0-4,543.0-4,424.0-4,832.0
Free Cash Flow-7.6%19,758.017,185.018,248.019,842.019,698.0

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)263.89
Basic Shares2,409.90
Market Cap635,948.1
Diluted Shares2,448.60
Fully Diluted Shares Outstanding2,448.60
Fully Diluted Market Cap646,161.1
+Consolidated Debt54,987.0
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-21,688.0
−Short-term Investments-363.0
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value669,247.1

Segment data

Revenue

by Products and services

  • Innovative Medicine64%
  • Medtech36%

Revenue

by Geography

  • United States57%
  • Europe23%
  • Asia-pacific, Africa15%
  • Western Hemisphere, Excluding U.s.5%

Related companies

Eli Lilly and Company

LLY US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US

Sanofi

SNY US